Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04783428 · ClinicalTrials.gov registry record
Tumor-induced Osteomalacia Disease Monitoring Program
A clinical trial of Tumor-induced Osteomalacia (TIO), sponsored by Ultragenyx Pharmaceutical.
- Active
- Registry status
- 23
- Enrollment target
- 6
- Study locations
NCT04783428 is a study of Tumor-induced Osteomalacia (TIO) that is active but no longer recruiting, run by Ultragenyx Pharmaceutical. The registered enrollment target is 23 participants. The trial reports 6 study locations across 6 states.
The verdict
NCT04783428, a study of Tumor-induced Osteomalacia (TIO), is active but no longer recruiting, sponsored by Ultragenyx Pharmaceutical.
- ACTIVE NOT RECRUITING
- Registry status
- 23 participants
- Enrollment target
- 6
- Study locations
Study Summary
The objectives of this observational study are to assess the long-term safety and long-term effectiveness of burosumab in patients with TIO who are being treated with burosumab as prescribed by their physician and to monitor the course of the underlying phosphaturic mesenchymal tumor (PMT) overtime in patients with TIO irrespective of their treatment status.
Conditions Studied
Interventions
- OTHER No intervention
Study Locations (6)
Connecticut
- Yale University - New Haven
Indiana
- Indiana University - Bloomington
Maryland
- Johns Hopkins University - Baltimore
Tennessee
- Vanderbilt University Medical Center - Nashville
Virginia
- University of Virginia - Charlottesville
Other
- IDIM - Instituto de Diagnóstico e Investigaciones Metabólicas - Buenos Aires
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2022-01-31 |
| Est. Completion | 2032-02-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04783428
The ClinicalTrials.gov registry entry for NCT04783428 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tumor-induced Osteomalacia (TIO) appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.
NCT04783428 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Connecticut, Indiana, Maryland.
Frequently Asked Questions
What is clinical trial NCT04783428 about?
NCT04783428 is a clinical study titled "Tumor-induced Osteomalacia Disease Monitoring Program". The objectives of this observational study are to assess the long-term safety and long-term effectiveness of burosumab in patients with TIO who are being treated with burosumab as prescribed by their physician and to monitor the course of the underlying phosphaturic mesenchymal tumor (PMT) overtime ...
What is the current status of trial NCT04783428?
This trial is currently active not recruiting. The enrollment target is 23 participants. The study started on 2022-01-31. Estimated completion is 2032-02-28.
What conditions does trial NCT04783428 study?
This clinical trial studies the following conditions: Tumor-induced Osteomalacia (TIO).
What interventions are being tested in trial NCT04783428?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT04783428?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04783428 being conducted?
This trial has 6 study locations across Connecticut, Indiana, Maryland, Tennessee, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumor-induced Osteomalacia (TIO)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.